Evidence map›Paper›PMID 35637961›Full record

ArticleInternational journal of biological sciences2022

Cold atmospheric plasmas target breast cancer stemness via modulating AQP3-19Y mediated AQP3-5K and FOXO1 K48-ubiquitination.

Xiaofeng Dai, Dongyan Cai, Peiyu Wang, Nan Nan, Lihui Yu, Zhifa Zhang, Renwu Zhou, Dong Hua, Jianying Zhang, Kostya Ken Ostrikov and 1 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Targeting proteostasis pathways for cancer therapy.Journal of pharmaceutical analysis · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Xiaofeng DaiWuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Dongyan CaiAffiliated Hospital of Jiangnan University, Wuxi 214122, China.
Peiyu WangInstitute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane 4059, Australia.
Nan NanWuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Lihui YuWuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Zhifa ZhangWuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Renwu ZhouSchool of Chemical and Biomolecular Engineering, University of Sydney, NSW 2006, Australia.
Dong HuaWuxi School of Medicine, Jiangnan University, Wuxi 214122, China.
Jianying ZhangBGI College & Henan Institute of Medical and Pharmaceutical Sciences in Academy of Medical Science, Zhengzhou University, 450052, China.
Kostya Ken OstrikovTranslational Research Institute, Woolloongabba, Queensland 4102, Australia.
Erik ThompsonTranslational Research Institute, Woolloongabba, Queensland 4102, Australia.
Jiangnan University · CNQueensland University of Technology · AUTranslational Research Institute · AUUniversity of Sydney · AUWuxi People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cold atmospheric plasma (CAP) is selective against many cancers with little side effect, yet its molecular mechanism remains unclear. Through whole transcriptome sequencing followed by assays

Indexed as

Aquaporin 3Breast NeoplasmsForkhead Box Protein O1Plasma GasesAtorvastatinFemaleHumansNeoplastic Stem CellsUbiquitinationAQP3 protein, humanAquaporin 3AtorvastatinForkhead Box Protein O1FOXO1 protein, humanPlasma GasesAQP3Atorvastatincancer stemnessCold atmospheric plasmaFOXO1SCAF11selective onco-therapyubiquitination

Identifiers

PMID35637961
PMCPMC9134899
OpenAlexW4285120904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.